DeutschNewstral
Article
jdsupra.com on 2024-03-18 21:49
Antitrust Lawsuit Brought Against Drug Manufacturer Based on Its Allegedly Improper Listing of Device Patents in the FDA’s Orange Book
Related news
- The FTC Strikes Again – Challenging the Listing of 300+ Patents in FDA’s Orange Bookjdsupra.com
- Lessons From FDA’s Warning Letter to Stem Cell Product Manufacturerjdsupra.com
- First Circuit Permits Antitrust Claims for Improperly Listing a Device Patent on the FDA’s Orange Book to Move Forwardjdsupra.com
FDA’s Medical Interference, Time for ESG Antitrust Action and other commentaryNew York Post- FDA’s Orange Book Listing Process: FTC Formally Joins the Frayjdsupra.com
- FTC Employs New Tactic in Effort Against Drug Makers Alleged to Have Improperly Listed Patents in the FDA’s Orange Bookjdsupra.com
- FDA’s Draft Guidance on Cosmetics Registration and Listing: A Good Reminder of End-of-Year Deadlinesjdsupra.com
Zillow files antitrust suit against real estate listing servicessanluisobispo.com- Antitrust Implications of HHS Proposal to Limit Manufacturer Rebatesjdsupra.com
- FTC Alleges Improper Orange Book Listing of Drug Delivery Device Patentsjdsupra.com
- Legislative Changes to FDA’s Orange Book and Purple Book Listing Requirementsjdsupra.com
- FTC Challenges 100+ Patents, Bringing Attention to Orange Book Patent Listing Requirementsjdsupra.com
- Investigations Newsletter: Medical Device Manufacturer Settles Improper Payment Allegations for $18 Millionjdsupra.com
- Restricted Distribution Patent Claims Are Not Method-of-Using Claims for the Purpose of Listing in FDA’s Orange Bookjdsupra.com
- Senators Urge DOJ to Develop Antitrust Guidance for Licensing of Standard Essential Patentsjdsupra.com
- Orange Book Patent Listing and Patent Certifications: Key Provisions in FDA’s Proposed Regulations Implementing the Medicare Modernization Act of 2003jdsupra.com
- Federal Court Criticizes Qualcomm Licensing Methods For SEP Patents, Finds Antitrust Violationsjdsupra.com